Companies To Watch: eXIthera

The name of this company, eXIthera, refers to its therapeutic aim, inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants. Its lead drug, an injectable coded EP-7041, has completed a Phase 1 clinical trial in healthy human subjects and moved to a program in cardiac surgery using the heart-lung machine, where life-threatening clotting and uncontrolled bleeding are common. The company also has begun earlier-stage development of an oral Factor XIa inhibitor.

Read More